Business Wire

International Energy Disputes Partner David Hesse Joins Hunton Andrews Kurth in London

22.8.2023 11:00:00 EEST | Business Wire | Press release

Share

David Hesse, an energy disputes attorney whose practice focuses on oil and gas litigation and arbitration matters with a strong emphasis on Africa has joined Hunton Andrews Kurth LLP as a partner in London.

Hesse advises states and national oil and gas companies on disputes, settlements, and upstream activities, as well as international tenders, refinery projects, farm-out agreements, and other contracts in the petroleum and petrochemical industries. His practice includes international commercial arbitration matters involving Anglophone and Francophone states and state entities in North, East, Central and West Africa.

Previously a partner with Clyde & Co., Hesse joins longtime colleague and collaborator Philip Mace as the newest additions to Hunton Andrews Kurth’s London-based energy team. Mace, who also recently joined the firm as a partner from Clyde & Co., is an experienced corporate lawyer whose practice is focused on energy and upstream oil and gas transactions.

“Robust global demand for large scale energy and infrastructure projects and the natural proliferation of disputes associated with those ventures continue to drive the need for a strong international arbitration and litigation practice,” said Tom Taylor, co-head of Hunton Andrews Kurth’s litigation team. “David is an outstanding lawyer whose experience and ability to navigate complex international disputes make him an ideal complement to the team.”

Hesse has extensive experience before international institutions including the International Chamber of Commerce (ICC) and International Centre for Settlement of Investment Disputes (ICSID). A selection of his notable representations prior to joining the firm include:

  • Advised the Government of Tanzania and the Tanzanian Electric Supply Company Limited (TANESCO) as co-lead international counsel with a local firm, in connection with related contract and treaty claims (ICSID) by Standard Chartered Bank.
  • Advised the Nigerian National Petroleum Corporation (NNPC) and supporting Nigerian counsel in connection with over $1 billion in claims by China National Offshore Oil Corporation (CNOOC) and South Atlantic Petroleum (SAPETRO) under a production sharing contract.
  • Advised the Government of Algeria and Sonatrach in connection with parallel proceedings (ICSID and UNCITRAL) by an oil and gas exploration company and an international shipping and logistics company for claims in excess of $8 billion relating to Algeria’s Windfall Profit Tax.
  • Advised the Government of Uganda and the Uganda Revenue Authority in connection with a $405 million claim by Heritage Oil (UNCITRAL) and a $473 million claim by Tullow Oil plc (ICSID) for recovery of capital gains tax under a production sharing agreement.
  • Advised ZCCM Investment Holdings PLC in connection with $2 billion in claims by Vedanta Resources Holdings Limited (UNCITRAL) relating to Konkola Copper Mines plc in Zambia.

“David’s practice complements our London-based projects and corporate offerings and reinforces our internationally recognized strength in the energy sector,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are excited to welcome David to the firm.”

A recognized lawyer in Chambers Global and Legal 500, Hesse is also an Honorary Lecturer at the Centre for Energy, Petroleum and Mineral Law and Policy at the University of Dundee and a lecturer at the CWC School for Energy. He is a regular speaker at international arbitration and energy conferences, including Juris Conference, GAR Energy Disputes, and GAR Live.

Hesse received his undergraduate degree from the University of Cincinnati, his LLB (Maîtres) from the Universitie de Paris – La Sorbonne, and his LLM from Columbia Law School.

Hunton Andrews Kurth’s international arbitration and transnational litigation practice represents clients around the globe. We regularly handle investor-state arbitrations before the International Centre for Settlement of Investment Disputes (ICSID), and commercial arbitrations before the International Court of Arbitration of the International Chamber of Commerce (ICC); the London Court of International Arbitration (LCIA); the Singapore International Arbitration Centre (SIAC); the Permanent Court of Arbitration in The Hague; and the American Arbitration Association (AAA) and its international division, the International Centre for Dispute Resolution (ICDR). We also work with clients in multi-jurisdictional matters, working closely with counsel in local forums.

About Hunton Andrews Kurth LLP

With over 900 lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP is a global firm that serves clients across a broad range of complex transactional, litigation and regulatory matters. The firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable experience in more than 100 distinct areas of practice, including privacy and cybersecurity, intellectual property, environmental, and mergers and acquisitions.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The PR Office
hak@theproffice.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye